Pediatric Vesicoureteral Reflux Medication

  • Author: Caleb P Nelson, MD, MPH; Chief Editor: Marc Cendron, MD   more...
 
Updated: Feb 9, 2012
 

Antibiotics

Class Summary

These are used for maintenance of sterile urine. Antibiotic agents used for prophylaxis in children with vesicoureteral reflux (VUR) are chosen for their efficacy in the urinary tract, safety, and tolerability. The typical dose is one fourth of the therapeutic dose. They are usually administered as suspensions once daily, typically in the evening to maximize overnight drug levels in the bladder. In neonates with antenatally diagnosed hydronephrosis and in infants younger than 8 weeks who have been treated for urinary tract infection (UTI), the agent of choice is amoxicillin. For older children, the most common antibiotics used are trimethoprim-sulfamethoxazole, nitrofurantoin, and penicillins. The cephalosporins are used less often.

View full drug information

Amoxicillin (Amoxil, Biomox, Trimox)

 

Interferes with synthesis of cell wall mucopeptides during active multiplication, resulting in bactericidal activity against susceptible bacteria. Is generally well tolerated, although has a higher rate of fecal resistance than some other agents. Metabolized effectively by newborns, making it a good choice for neonates.

View full drug information

Sulfamethoxazole and trimethoprim (Bactrim, Septra, Cotrim)

 

Inhibit bacterial growth by inhibiting synthesis of dihydrofolic acid. DOC in children >6-8 wk. The maturing hepatobiliary system is able to process trimethoprim-sulfamethoxazole combination agents, which have an excellent urinary concentration profile and tend to cause fewer fecal resistance problems. Well tolerated orally.

View full drug information

Nitrofurantoin (Furadantin, Macrodantin)

 

Synthetic nitrofuran that interferes with bacterial carbohydrate metabolism by inhibiting acetylcoenzyme A. Bacteriostatic at low concentrations (5-10 mcg/mL) and bactericidal at higher concentrations.

Another common urinary antiseptic agent for children >8 wk. Unpleasant taste of the liquid form makes it unacceptable to some children. Older children who can tolerate tablets do well with this medication.

Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Caleb P Nelson, MD, MPH  Assistant Professor of Surgery (Urology), Department of Urology, Harvard Medical School; Consulting Staff, Department of Urology, Children's Hospital Boston

Caleb P Nelson, MD, MPH is a member of the following medical societies: American Urological Association, Endourological Society, Phi Beta Kappa, Society for Fetal Urology, and Society for Pediatric Urology

Disclosure: Nothing to disclose.

Coauthor(s)

Harry P Koo, MD  Chairman of Urology Division and Director of Pediatric Urology, Professor of Surgery, Virginia Commonwealth University School of Medicine, Medical College of Virginia; Director of Urology, Children's Hospital of Richmond

Harry P Koo, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Surgeons, and American Urological Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Bartley G Cilento, Jr, MD  Instructor, Department of Surgery, Division of Urology, Children's Hospital of Boston and Harvard Medical School

Bartley G Cilento, Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Urological Association, and Massachusetts Medical Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Martin David Bomalaski, MD, FAAP  Pediatric Urologist, Alpine Urology

Martin David Bomalaski, MD, FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, and American Urological Association

Disclosure: Nothing to disclose.

Daniel Rauch, MD, FAAP  Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine

Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine

Disclosure: Baxter Honoraria Consulting

Chief Editor

Marc Cendron, MD  Associate Professor of Surgery, Harvard School of Medicine; Consulting Staff, Department of Urological Surgery, Children's Hospital Boston

Marc Cendron, MD is a member of the following medical societies: American Academy of Pediatrics, American Urological Association, European Society for Paediatric Urology, Johns Hopkins Medical and Surgical Association, New Hampshire Medical Society, Society for Fetal Urology, and Society for Pediatric Urology

Disclosure: Nothing to disclose.

References

  1. Academy of Pediatrics. Committee on Quality Improvement. Subcommittee on UTI. Practice parameter: the diagnosis, treatment, and evaluation of the initial urinary tract infection in febrile infants and young children. Pediatrics. Apr 1999;103(4 Pt 1):843-52. [Medline].

  2. Smellie JM, Prescod NP, Shaw PJ, et al. Childhood reflux and urinary infection: a follow-up of 10-41 years in 226 adults. Pediatr Nephrol. Nov 1998;12(9):727-36. [Medline].

  3. Walker RD. Vesicoureteral reflux and urinary tract infection in children. In: Gillenwater JY, Grayhack JT, eds. Adult and Pediatric Urology. 3rd ed. Mosby-Year Book; 1996:2259-96.

  4. Ransley PG, Risdon RA. Reflux nephropathy: effects of antimicrobial therapy on the evolution of the early pyelonephritic scar. Kidney Int. Dec 1981;20(6):- Risdon RA. [Medline].

  5. Lee YJ, Lee JH, Park YS. Risk Factors for Renal Scar Formation in Infants With First Episode of Acute Pyelonephritis: A Prospective Clinical Study. J Urol. Jan 18 2012;[Medline].

  6. Weiss R, Duckett J, Spitzer A. Results of a randomized clinical trial of medical versus surgical management of infants and children with grades III and IV primary vesicoureteral reflux (United States). The International Reflux Study in Children. J Urol. Nov 1992;148(5 Pt 2):1667-73. [Medline].

  7. Elder JS, Diaz M, Caldamone AA, et al. Endoscopic therapy for vesicoureteral reflux: a meta-analysis. I. Reflux resolution and urinary tract infection. J Urol. Feb 2006;175(2):716-22. [Medline].

  8. Atala A, Keating MA. Vesicoureteral reflux and megaureter. In: Campbell, MF, Retik AB, Vaughan E, Walsh PC, eds. Campbell's Urology. 7th ed. Philadelphia, PA: WB Saunders Co; 1997:1859-916.

  9. Belman AB. Vesicoureteral reflux. Pediatr Clin North Am. Oct 1997;44(5):1171-90. [Medline].

  10. Birmingham Reflux Study Group. Prospective trial of operative versus non-operative treatment of severe vesicoureteric reflux in children: five years' observation. Br Med J (Clin Res Ed). Jul 25 1987;295(6592):237-41. [Medline].

  11. Edmondson JD, Maizels M, Alpert SA, Kirsch AJ, Hanna MK, Weiser AC, et al. Multi-institutional experience with PIC cystography--incidence of occult vesicoureteral reflux in children with febrile urinary tract infections. Urology. Mar 2006;67(3):608-11. [Medline].

  12. International Reflux Study Committee. Medical versus surgical treatment of primary vesicoureteral reflux. Pediatrics. Mar 1981;67(3):392-400. [Medline].

  13. Keren R, Carpenter MA, Hoberman A, Shaikh N, Matoo TK, Chesney RW, et al. Rationale and design issues of the Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) study. Pediatrics. Dec 2008;122 Suppl 5:S240-50. [Medline]. [Full Text].

  14. Kirsch AJ, Perez-Brayfield M, Smith EA, Scherz HC. The modified sting procedure to correct vesicoureteral reflux: improved results with submucosal implantation within the intramural ureter. J Urol. Jun 2004;171(6 Pt 1):2413-6. [Medline].

  15. Koo HP, Bloom DA. Lower ureteral reconstruction. Urol Clin North Am. Feb 1999;26(1):167-73, x. [Medline].

  16. Routh JC, Inman BA, Reinberg Y. Dextranomer/hyaluronic acid for pediatric vesicoureteral reflux: systematic review. Pediatrics. May 2010;125(5):1010-9. [Medline].

  17. Vallee JP, Vallee MP, Greenfield SP, et al. Contemporary incidence of morbidity related to vesicoureteral reflux. Urology. Apr 1999;53(4):812-5. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.